Numinus Wellness Inc
Change company Symbol lookup
Select an option...
NUMIF Numinus Wellness Inc
JBGS JBG SMITH Properties
RNWWW ReNew Energy Global Equity Warrant Exp 23rd Aug 2026 *W EXP 08/23/2026
RVPH Reviva Pharmaceuticals Holdings, Inc.
TPR Tapestry Inc
BGRY Berkshire Grey Inc
BKNG Booking Holdings Inc
UHT Universal Health Realty Income Trust
BBVA Banco Bilbao Vizcaya Argentaria SA
RILY B Riley Financial Inc
Go

Health Care : Pharmaceuticals | Small Cap Growth
Based in Canada
Company profile

Numinus Wellness Inc. is a Canada-based mental health care company. The Company develops proprietary, psychedelic-centered, therapeutic products and services through its own laboratory and research and development processes. The Company operates through three segments: Research Operations, the Canadian Clinic Network, and the U.S. Clinic Network. Its Research Operations is focused on licensed psychedelic research and provides clinical research management services to academic institutions and biotechnology companies. The Canadian clinic network consists of Numinus Health Corp., Mindspace, and the NCT. It offers services, such as ketamine-assisted psychotherapy (KAP) for depression, neurological care and psychotherapy and counseling by registered psychologists. The U.S. Clinic Network consists of Cedar Psychiatry and Foundations for Change. It offers services, such as KAP for depression and psychotherapy and counseling by registered psychologists in the United States.

Closing Price
$0.2059
Day's Change
0.0038 (1.89%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.217
Day's Low
0.20
Volume
(Heavy Day)
Volume:
113,550

10-day average volume:
87,332
113,550

Display:

Providers:

UpdateCancel
6 providers
February 01, 2023
Numinus Receives Clinical Trial Application Approval from Health Canada for Experiential Psychedelic-Assisted Therapy Training using Psilocybe Cubensis Tea

-- Clinical trial will be the first to test whole Psilocybemushrooms for safety and efficacy in a clinical setting; study is expected to provide important data to support increased access to psilocybin-assisted therapy. (PR Newswire)

January 16, 2023
Numinus Wellness Inc. Reports Q1 2023 Results

-- Q1 2023 revenues grew 618% year-over-year to $5.7 million -- Q1 2023 gross margin grew to 41.9% from 31.5% in prior quarter -- Gross profit of $2.4 million, an increase of $1.1 million from prior quarter (PR Newswire)

January 04, 2023
Numinus to Host Q1 2023 Results Conference Call on January 16, 2023

Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter...(PR Newswire)

December 16, 2022
December 13, 2022
December 12, 2022
Numinus to Participate in the KCSA Mental Health Virtual Investor Conference on December 15, 2022

Numinus Wellness Inc.("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO...(PR Newswire)

December 08, 2022
Numinus Submits Clinical Trial Application to Health Canada for Experiential Psilocybin-Assisted Therapy Training Research

-- New clinical trial will provide experiential training to therapists learning to conduct psilocybin-assisted therapy. -- Clinical trial dosing will use Numinus Bioscience's Psilocybin Tea, EnfiniTea - one of the first Phase 1 clinical trials that...(PR Newswire)

November 30, 2022
IIROC Trade Resumption - NUMI

Trading resumes in: Company: Numinus Wellness Inc. TSX Symbol: NUMI All Issues: Yes Resumption (ET): 8:00 AM IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are...(PR Newswire)

November 29, 2022
IIROC Trading Halt - NUMI

The following issues have been halted by IIROC: Company: Numinus Wellness Inc. TSX Symbol: NUMI All Issues: Yes Reason: Pending News Halt Time (ET): 4:07 PM IIROC can make a decision to impose a temporary suspension (halt) of trading in a security...(PR Newswire)

Numinus Wellness Inc. Reports Q4 2022 and Annual Results

-- Q4 2022 revenues grew 643% year-over-year to $4.2 million -- Q4 2022 gross margin grew to 31.5%, generated $1.3 million of gross profit -- Completed acquisition of Novamind, positioning Numinus as a leading, integrated mental healthcare company...(PR Newswire)

November 22, 2022
Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, December 8, 2022

Numinus Wellness Inc.("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and...(PR Newswire)

November 15, 2022
Numinus to Host Q4 and Year End 2022 Results Conference Call on November 29, 2022

Numinus Wellness Inc.("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter...(PR Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.